Alkermes plc ALKS
44.54 USD -1.35 (-2.94%)
At closeNov 5, 2026, 4:00 PM EST
44.54 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
44.42 Day range 46.55
27.00 52-week range 55.67
- YTD
- +59.19%
- 1 year
- +43.35%
News
benzinga.com RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57 RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $56 to $57.- benzinga.com Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68 Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $65 to $68.
benzinga.com HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50 HC Wainwright & Co. analyst Douglas Tsao maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $43 to $50.
seekingalpha.com Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson -…
marketbeat.com What Alkermes (ALKS) Said on Its Q3 Earnings Call Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development…
zacks.com Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Alkermes Q3 2026 Earnings Call Transcript Alkermes (NASDAQ:ALKS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
benzinga.com Alkermes Q3 EPS $0.09 Beats $(0.06) Estimate, Sales $480.100M Beat $463.606M Estimate Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.06) by 250 percent. This is a 81.63 percent decrease over earnings of $0.49 per…
benzinga.com Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.822B Est Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.822 billion estimate.
businesswire.com Alkermes plc Reports Third Quarter 2026 Financial Results DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and…
defenseworld.net Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast Vericel (NASDAQ: VCEL - Get Free Report) and Alkermes (NASDAQ: ALKS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
businesswire.com Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in…
benzinga.com Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026 — Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be…